Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome

Thrombosis Research

Volumn 114, Issue 5-6 SPEC. ISS., 2004, Pages 443-446

  Crowther, Mark A ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Anticoagulant; Antiphospholipid antibodies; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SHORT SURVEY; THROMBOSIS PREVENTION; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

EID: 7044225944     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.011     Document Type: Article

References (16)

1. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 104:1998;332-338
2. Kearon C., Gent M., Hirsh J., Weitz J.I., Kovacs M.J., Anderson D., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med. 340:1999;901-907
3. Brunner H.I., Chan W.S., Ginsberg J.S., Feldman B.M. Long-term anticoagulation is preferable for patients with antiphospholipid antibody syndrome. Result of a decision analysis. J. Rheumatol. 29:2002;490-501
4. Petri M. Management of thrombosis in antiphospholipid antibody syndrome. Rheum. Dis. Clin. North Am. 27:2001;633-642
5. Hirsh J., Dalen J., Anderson D.R., Poller L., Bussey H., Ansell J., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:2001;8 S-21S
6. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332:1995;993-997
7. Rosove M.H., Brewer P.M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117:1992;303-308
8. Crowther M.A., Ginsberg J.S., Gent M., Julian J., Costantini L., Kovacs M.J., et al. A randomized trial of two intensities of warfarin (international normalized ratio of 2.0 to 3.0 versus 3.1 to 4.0) for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies. N. Engl. J. Med. 349:2003;1133-1138
9. Finazzi G., Marchioli R., Barbui T. A randomized clinical trial of oral anticoauglant therapy in patients with antiphospholipid antibody syndrome: the WAPS study. J. Thromb. Haemost. 1:2003;OC365
10. Oden A., Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ. 325:2002;1073-1075
11. Kearon C., Ginsberg J.S., Anderson D.R., Kovacs M.J., Wells P., Julian J.A., et al. for the SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J. Thromb Haemost. 2004;. in press
12. Kearon C., Ginsberg J.S., Kovacs M.J., Anderson D.R., Wells P., Julian J.A., et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N. Engl. J. Med. 349:2003;631-639
13. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L., Sciacca R.R., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 291:2004;576-584
14. Mohr J.P., Thompson J., Lazar R.M., Levin B., Sacco R.L., Furie K.L., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med. 345:2002;1444-1451
15. van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 360:2002;109-113
16. Hurlen M., Smith P., Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand. Cardiovasc. J. 34:2000;168-171